Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

Fortis Healthcare Ltd.

(NSE:FORTIS)

Select Model

Rating:60Neutral

Price Target:INR 808.00▲(4.96% Upside)

Action:reiterated

Date:08/24/26

The score is supported by solid underlying financial performance (profitability improvement and conservative leverage), but is held back by weak technical momentum and a stretched valuation (high P/E with very low dividend yield).

Positive Factors

Steady Revenue GrowthSteady multi-year revenue expansion indicates continued demand for Fortis Healthcare’s hospital and clinical services. This growth can support capacity development, broaden the company’s care footprint, and provide a durable base for improving earnings over the next several quarters.

Negative Factors

Uneven Cash ConversionPositive operating cash flow is not consistently converting into equivalent free cash flow, which can limit funds available for expansion, debt reduction, or shareholder returns. The gap suggests ongoing working-capital, build-out, or other cash uses may persist alongside reported profits.

Fortis Healthcare Ltd. (FORTIS) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 579.92B
Dividend Yield: 0.13%
Average Volume (3M): 213.63K
Price to Earnings (P/E): 55.3
Beta (1Y): 1.04
Revenue Growth: 17.50%
EPS Growth: 20.65%
Country: India
Employees: 14,649
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Established in 1996 and headquartered in Gurugram, India, Fortis Healthcare Limited operates as an integrated provider of healthcare services. The company extends its offerings, which encompass secondary, tertiary, and quaternary medical care, across...

Fortis Healthcare Ltd. Financial Statement Overview

Summary

Strong income statement and balance sheet signals (steady revenue growth, improved profitability since 2021, and low leverage), but the cash-flow profile is the main drag: cash conversion vs. earnings is uneven and free cash flow is volatile and modest relative to profits.

Income Statement

78Positive

Balance Sheet

82Very Positive

Cash Flow

66Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	95.06B	91.28B	77.86B	68.97B	62.98B	57.18B
Gross Profit	38.83B	33.43B	45.86B	39.73B	23.08B	32.25B
EBITDA	21.45B	21.30B	15.80B	12.62B	11.00B	10.61B
Net Income	10.48B	10.42B	7.74B	5.99B	5.89B	5.55B
Balance Sheet
Total Assets	0	159.66B	136.92B	132.89B	124.34B	118.85B
Cash, Cash Equivalents and Short-Term Investments	5.59B	5.61B	5.08B	6.00B	3.66B	4.13B
Total Debt	0	34.73B	24.75B	11.55B	9.26B	12.55B
Total Liabilities	-101.69B	57.98B	45.22B	47.33B	43.33B	48.76B
Stockholders Equity	101.69B	98.96B	89.17B	76.63B	72.42B	61.78B
Cash Flow
Free Cash Flow	800.30M	4.39B	5.77B	1.58B	3.75B	6.50B
Operating Cash Flow	6.76B	13.84B	14.24B	11.00B	8.22B	8.65B
Investing Cash Flow	-9.86B	-15.83B	-7.79B	-8.86B	-3.74B	-5.14B
Financing Cash Flow	2.46B	4.26B	-7.14B	-864.58M	-4.71B	-5.17B

Fortis Healthcare Ltd. Technical Analysis

Technical Analysis SentimentNeutral

Last Price769.80

Price Trends

50DMA835.66Negative

100DMA894.91Negative

200DMA895.86Negative

Market Momentum

MACD-24.78Negative

RSI46.93Neutral

STOCH92.37Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Neutral. The current price of 769.80 is above the 20-day moving average (MA) of 752.55, below the 50-day MA of 835.66, and below the 200-day MA of 895.86, indicating a neutral trend. The MACD of -24.78 indicates Negative momentum. The RSI at 46.93 is Neutral, neither overbought nor oversold. The STOCH value of 92.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:FORTIS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:MEDANTA	79Outperform	INR 341.22B	61.37	―	0.08%	21.27%	4.09%
IN:ASTERDM	67Neutral	INR 595.70B	110.40	―	0.59%	15.70%	-2.76%
IN:NH	67Neutral	INR 351.44B	42.88	―	0.26%	71.40%	1.76%
IN:APOLLOHOSP	62Neutral	INR 1.21T	58.13	―	0.24%	17.20%	32.79%
IN:MAXHEALTH	60Neutral	INR 837.05B	57.45	―	0.23%	15.17%	1.63%
IN:FORTIS	60Neutral	INR 581.17B	55.34	―	0.13%	17.50%	20.65%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:FORTIS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:FORTIS	Fortis Healthcare Ltd.	769.80	-259.46	-25.21%
IN:APOLLOHOSP	Apollo Hospitals Enterprise Limited	8400.00	594.57	7.62%
IN:ASTERDM	Aster DM Healthcare Ltd.	683.40	4.80	0.71%
IN:MAXHEALTH	Max Healthcare Institute Ltd	860.00	-284.47	-24.86%
IN:MEDANTA	Global Health Limited	1269.05	-6.25	-0.49%
IN:NH	Narayana Hrudayalaya Ltd.	1719.70	-62.04	-3.48%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Subsidiary Takes 26% Stake in Captive Solar SPV to Cut Energy Costs

Oct 12, 2026

Fortis Healthcare’s subsidiary Fortis Hospotel Limited has agreed to acquire 26% equity in Clean Max Sau Private Limited, a special purpose vehicle set up to develop, operate and maintain a captive solar power generation project in Haryana. The...

Fortis, IHH to Cooperate With Court-Ordered Forensic Audit on 2018 Stake Deal

Sep 29, 2026

Fortis Healthcare has disclosed that the Supreme Court of India has disposed of its Special Leave Petition challenging a Delhi High Court order mandating a forensic audit of the company and related observations. The development follows earlier regula...

Supreme Court Clears Independent Forensic Audit of Fortis Healthcare

Sep 27, 2026

Fortis Healthcare Ltd. said the Supreme Court of India has disposed of its Special Leave Petition challenging a Delhi High Court order that had directed a forensic audit of the company in connection with the Daiichi Sankyo vs. Singh Brothers dispute....

Fortis, IHH Update Markets as Tokyo Court Dismisses NTK Claim Against Daiichi Sankyo

Sep 11, 2026

Fortis Healthcare has updated Indian exchanges on a key legal matter involving its promoter shareholder Northern TK Venture Pte Ltd and Daiichi Sankyo in the Tokyo District Court. The disclosure is made under SEBI listing norms, underscoring the case...

Fortis Healthcare Posts Audio of Investor Meet on Company Website

Sep 4, 2026

Fortis Healthcare Ltd. has notified the stock exchanges that it has made available an audio recording of an investors and analysts meeting held on September 4, 2026. The meeting, conducted under the disclosure framework of SEBI’s Listing Obliga...

Delhi High Court Orders Forensic Audit on Fortis Promoter Share Dissipation; No Liability on Company

Aug 31, 2026

Fortis Healthcare has disclosed that the Delhi High Court has ordered a forensic audit linked to applications filed in the long-running Daiichi Sankyo dispute involving former promoters Malvinder and Shivinder Singh. The audit will examine the dissip...

Fortis Subsidiary Agilus Diagnostics Moves to Merge Pathlab Units in Intra-Group Restructuring

Aug 5, 2026

Fortis Healthcare’s material subsidiary Agilus Diagnostics Limited has approved an intra-group restructuring that will merge its wholly owned subsidiaries, Agilus Pathlabs Private Limited and DDRC Agilus Pathlabs Limited, into Agilus Diagnostic...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 24, 2026

Fortis Healthcare Ltd. AI Stock Analysis